Repligen Corporation (RGEN)
After hours:
| Previous close | 164.20 |
| Open | 159.00 |
| Bid | 158.15 x 100 |
| Ask | 158.70 x 300 |
| Day's range | 152.25 - 164.06 |
| 52-week range | 110.45 - 211.13 |
| Volume | |
| Avg. volume | 491,549 |
| Market cap | 8.843B |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | 214.00 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Repligen Reports First Quarter 2024 Financial Results
Reports first quarter revenue of $151 million Increased new modalities revenue by 16% year-over-yearIncreased Filtration (non-COVID) revenue by 12% year-over-yearAchieved a nine-month book-to-bill ratio of 1.03 WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter (Q1) of 2024, covering the three-month period ended March 31, 2024. The compa
- GlobeNewswire
Repligen to Report First Quarter 2024 Financial Results
Webcast and Conference Call to Be Held Wednesday, May 1, 2024, at 8:30 a.m. ETWALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2024 financial results on Wednesday, May 1, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- month reporting period ended March 31, 2024. Th
- GlobeNewswire
Repligen Appoints Maggie A. Pax to Board of Directors
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax. This appointment expands the size of Repligen’s board from eight to nine members. Ms. Pax brings to Repligen over 25 years of experience leading the development and execution of growth strategies for global companies. This includes eight years with Thermo Fisher Scientific, where, from 2016–2020, she ser
